[메자닌 투자파일] 이엠텍, 안트로젠 지분 유동화…제품사업 베팅

EMTek's convertible bond issuance backed by Antrogen biotech stakes marks a strategic pivot from component manufacturing to higher-margin product businesses (e-cigarettes and auto-injectors), indicating that product commercialization is critical for future profitability. Despite revenue growth, the company's tight cash position forced it to monetize cross-holdings rather than pursue traditional financing—signaling confidence in near-term product launches, especially as auto-injector technology approaches FDA approval. This approach demonstrates how manufacturers are leveraging strategic equity holdings to fund new ventures without immediate shareholder dilution.